<table>
<thead>
<tr>
<th>Highlights of This Issue</th>
<th>1307</th>
</tr>
</thead>
</table>

**SPECIAL FEATURES**

**CCR Translations**

1309  **Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies**
Kim-Hien T. Dao and Jeffrey W. Tyner  
*See article, p. 1422*

1312  **New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma**
Riccardo Lencioni  
*See article, p. 1503*

**CCR Perspectives in Drug Approval**

1315  **Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?**
Gilles Vassal, Birgit Geoerger, and Bruce Morland

**Statistics in CCR**

1326  **Borrowing Information across Subgroups in Phase II Trials: Is It Useful?**
Boris Freidlin and Edward L. Korn

**CCR Drug Updates**

1335  **Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer**
Jean Hoffman-Censits and Wm. Kevin Kelly

**Molecular Pathways**

1340  **Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity**
Lisa A. Ridnour, Robert Y.S. Cheng, Christopher H. Switzer, Julie L. Heinecke, Stefan Amba, Sharon Glynn, Howard A. Young, Giorgio Trinchieri, and David A. Wink

1347  **Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer**
Jessica Brownell and Stephen J. Poljak

**HUMAN CANCER BIOLOGY**

1353  **Murine Microenvironment Metaportes Associate with Human Cancer Etiology and Intrinsic Subtypes**
David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, and Mary Helen Barcellos-Hoff

1363  **PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction**
Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Noriomi Matsumura, Tsukasa Baba, Ken Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharna, Kenzo Kosaka, and Ikao Konishi

1375  **Rab25 Regulates Invasion and Metastasis in Head and Neck Cancer**
Panomwat Amornphimoltham, Kamol Recharhe, Jamie Thompson, Andrius Masedunskas, Kanta Soft-Charanankul, Vyomesh Patel, Alfredo Molinolo, J. Silvio Gutkind, and Roberto Weigert

1389  **MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer**
San-Jian Yu, Jing-Jing Hu, Xiu-Ying Kuang, Jian-Min Lao, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Hou-Yan Song, and Zhi-Ming Shao

1400  **HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification**
Jianghua Zheng, Jinglong Wang, Xueqing Sun, Mingang Hao, Tao Ding, Dan Xiong, Xuemin Wang, Yu Zhu, Gang Xiao, Guangsun Cheng, Meizhong Zhao, Jian Zhang, and Jianhua Wang

1411  **Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer**
Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia
Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yosuke Minami, Shinya Kimura, Taira Maekawa, Tomoki Naoe, and Kazuma Ohyashiki
See commentary, p. 1309

Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition
Ying Zhang, Kaitlyn E. Farenholtz, Yanzhi Yang, Fadila Guessous, Charles G. diPierro, Valerie S. Calvert, Jianghong Deng, David Schiff, Wenjun Xin, Jae K. Lee, Benjamin Purov, James Christensen, Emanuel Petricoin, and Roger Abounader

Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-kB
Lorenz Bastian, Jana Hof, Madlen Pfau, Iduna Fichtner, Cornelia Eckert, Günter Henze, Javier Prada, Arend von Stackelberg, Karl Seeger, and Shabnam Shalapour

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Eric I. Zimmerman, Shuiliing Hu, Justin L. Roberts, Alice A. Gibson, Shelley J. Orwick, Lie Li, Alex Sparreboom, and Sharyn D. Baker

Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells

Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells
Eric D. Mortenson, SaeGwang Park, Zhujun Jiang, Shengdian Wang, and Yang-Xin Fu
Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Ruben Niesvizky, Tamer M. Mark, Maureen Ward, David S. Jayabal, Roger N. Pearse, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiporah B. Shore, Faiza Zafar, Karen Pekle, Zhaoying Xiang, Scott Ely, Donna Skerret, Selina Chen-Kiang, Morton Coleman, and Maureen E. Lane

Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Firas L. T. Al-Ubaidi, Niklas Schultz, Olga Loseva, Lars Egevad, Torvald Granfors, and Thomas Hellday

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes

Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz, Andrew Brenner, Eric T. Wong, April Eichler, David Schiff, Morris D. Groves, Tom Mikkelsen, Steve Rosenfeld, John Sarantopoulos, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, and David Liu

A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Hao Tang, Guanghua Xiao, Carmen Behrens, Joan Schiller, Jeffrey Allen, Chi-Wan Chow, Milind Suraoakar, Alejandro Corvalan, Jianhua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, and Yang Xie

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Irinotecan or Paclitaxel in Early-Stage Breast Cancer
Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, and David Liu

Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients
Antonio Giordano, Brian L. Egleston, David Hajage, Joseph Bland, Gabriel N. Hortobagyi, James M. Reuben, Jean-Yves Pierga, Massimo Cristofanilli, and Francois-Clement Bidard

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC
Rathi N. Pillai, Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, Vijay A. Varma, Dacian Bonta, James G. Herman, Malcolm V. Brock, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes

A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer

Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Hao Tang, Guanghua Xiao, Carmen Behrens, Joan Schiller, Jeffrey Allen, Chi-Wan Chow, Milind Suraoakar, Alejandro Corvalan, Jianhua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, and Yang Xie

A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer

Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy
ABOUT THE COVER

The microphotograph shows the induction of apoptosis after combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in a xenograft mouse model of acute lymphoblastic leukemia (ALL). Human B-cell precursor ALL cells were injected subcutaneously into nonobese diabetic/severe combined immunodeficient mice. Tumor sections after treatments were stained with mAbs against human CD10 (red) indicating leukemia cells, cleaved caspase-3 (green) indicating apoptotic cells, and 4',6-diamidino-2-phenylindole (nuclei, blue). For details, please see the article by Bastian and colleagues on page 1445 of this issue.
Clinical Cancer Research

19 (6)


| Updated version | Access the most recent version of this article at:  
| http://clincancerres.aacrjournals.org/content/19/6 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |